← Therapy pipeline
Investigational · Obesity development

Conveglipron (HDM1002)

HDM1002 · Huadong Medicine

Oral GLP-1 receptor agonist under regulatory review for weight management in China.

GLP-1
Obesity stageFiled for reviewUpdated as of November 2026
SponsorHuadong Medicine
TargetsGLP-1
RouteOral tablet
DevelopmentObesity-specific
01 / Evidence

Reported findings

China Phase 3 update

Sponsor reports that the obesity Phase 3 primary endpoint was met.

Numerical Phase 3 results were not included in the interim report. An ADA 2026 Phase 2 abstract is available; U.S. obesity development has not been confirmed.

Source report ↗
02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Oral · ChinaOral tablet
FiledChina weight-management application accepted for review
Milestone → next

Latest: Huadong reported that China’s National Medical Products Administration accepted the conveglipron tablet marketing application for weight management on November 2, 2026.

Next: China regulatory review and any confirmed development outside China.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies1 record

Phase 3

HDM1002 obesity Phase 3

Weight management
Study: Planned / not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

China obesity study; sponsor reports the primary endpoint was met.

Phase 2 studies1 record

Phase 2

HDM1002 obesity Phase 2

Weight management
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

Earlier obesity study; Phase 2 results were presented at ADA 2026.